Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 123, Issue 1, pp 85–87 | Cite as

Clinical significance of the tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer

  • N. E. Kushlinskii
  • N. V. Lyubimova
  • A. O. Lemeshko
  • A. V. Vasil’ev
  • M. I. Davydov
Experimental Methods For Clinical Practice

Abstract

The diagnostic validity of CYFRA 21-1 and neuron-specific enolase is assessed in patients with lung cancer. Serum contents of CYFRA 21-1 and neuron-specific enolase are increased, respectively, in 74 and 67% of patients with various histological variants of lung cancer. Diagnostic sensitivity of CYFRA was 77.2% in lung cancer other than the small cell variant and 76% in small cell lung cancer. A correlation between the CYFRA content and the tumor size in patients with squamous and other than small cell lung cancer is demonstrated. In patients with spread small cell cancer, serum enolase content tends to increase compared with that in patients with localized small cell cancer. Both CYFRA and enolase are sensitive lung tumor markers in the diagnostics and evaluation of the extent of tumor spread.

Key Words

tumor markers CYFRA 21-1 neuron-specific enolase lung cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Bodenmuller, D. Banauch, E. Ofenloch,et al., in:Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the 90th, R. Klapdor (Ed.), Munchen (1992), pp. 137–138.Google Scholar
  2. 2.
    E. H. Cooper, T. A. W. Splinter, D. A. Brown,et al., Br. J. Cancer,52, 333–338 (1985).PubMedGoogle Scholar
  3. 3.
    W. Ebert, B. Leichtweis, B. Schapohler, and T. H. Muley,Tumordiagn. Ther.,14, 91–99 (1993).Google Scholar
  4. 4.
    G. Jaques, G. Bepler, R. Holle,et al., Cancer,62, 125–134 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    P. W. M. Johnson, S. P. Joel, S. Love,et al., Br. J. Cancer,67, 760–766 (1993).PubMedGoogle Scholar
  6. 6.
    L. G. M. Jorgrnsen, H. H. Hansen, and E. N. Cooper,Eur. J. Cancer Clin. Oncol.,25, No. 1, 123–128 (1989).CrossRefGoogle Scholar
  7. 7.
    D. Rastel,Tumor Marker Update,7, 55–63 (1995).Google Scholar
  8. 8.
    K. Sorensen, U. Brodbeck, E. Paus, and B. Norgaard-Pedersen,Clin. Chim. Acta,175, 337–344 (1988).PubMedCrossRefGoogle Scholar
  9. 9.
    P. Stieber, H. Dienemann, U. Hasholzner,et al., J. Clin. Chem. Clin. Biochem.,31, 689–694 (1993).Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • N. E. Kushlinskii
    • 1
  • N. V. Lyubimova
    • 1
  • A. O. Lemeshko
    • 1
  • A. V. Vasil’ev
    • 1
  • M. I. Davydov
    • 1
  1. 1.Laboratory of Clinical Biochemistry, Department of Thoracal Oncology, Department of Pathological Anatomy of Human Tumors, Research Institute Clinical Oncology, N. N. Blokhin Oncology Research CenterRussian Academy of Medical SciencesMoscow

Personalised recommendations